Aspira Women’s Health raises $3.06 million through equity financing

Published 18/09/2025, 12:08
Aspira Women’s Health raises $3.06 million through equity financing

AUSTIN - Aspira Women’s Health Inc. (OTCQB:AWHL) has secured $3.06 million in equity capital from existing and new investors, the women’s health diagnostics company announced Thursday. The company, currently valued at approximately $15 million, has been experiencing significant cash burn according to InvestingPro analysis, making this capital raise crucial for operations.

The financing includes a $2.95 million private placement of units consisting of common stock and warrants, plus an additional $112,500 from the exercise of previously issued warrants. The company sold units at $0.45 each, with each unit comprising one common share and 75% of one warrant. InvestingPro data shows the stock is currently trading below its Fair Value, despite showing impressive momentum with a 254% return over the past six months.

The transaction resulted in the issuance of 6,550,000 additional common shares and 4,912,500 new warrants. Each warrant entitles the holder to purchase one share of common stock at $0.75 per share over a five-year term.

Several members of Aspira’s Board of Directors participated in the private placement. The company stated that proceeds will support ongoing commercial activities, general corporate purposes, and working capital.

"During the investor due diligence process, we articulated our business plans for our existing commercial portfolio of revenue generating products, as well as our anticipated innovations," said Jack Fraser, Chairman of Aspira, in the press release.

Aspira Women’s Health develops AI-enhanced diagnostic tests for gynecologic diseases. Its current product portfolio includes OvaWatch and Ova1Plus, blood tests designed to assess ovarian cancer risk in women with adnexal masses. The company is also developing tests for endometriosis. With annual revenue of $9.29 million and analysts forecasting significant sales growth, detailed analysis of Aspira’s potential is available in the comprehensive Pro Research Report on InvestingPro, along with 10+ additional ProTips and key metrics.

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

In other recent news, Aspira Women’s Health has made significant changes to its leadership team. The company announced the appointment of Brian Hungerford as the new chief financial officer and principal accounting officer. Hungerford, who has over 20 years of experience in various industries, previously held the CFO position at Kiromic Biopharma, Inc. This appointment follows a Master Service Agreement and Statement of Work approved by the board of directors. Additionally, Aspira Women’s Health has welcomed Jane Pine Wood to its board of directors. Wood, an attorney with more than 38 years of experience, has been involved with laboratories and healthcare providers throughout her career. She is currently with McDonald Hopkins, LLC, where she has served as a partner and board member. These appointments reflect Aspira Women’s Health’s ongoing efforts to strengthen its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.